Читать книгу Transporters and Drug-Metabolizing Enzymes in Drug Toxicity - Albert P. Li - Страница 58

Felbamate is an anticonvulsant with a dual mechanism of action both as an agonist of gamma‐aminobutyric acid (GABA) receptors and also an antagonist of N‐methyl‐D‐aspartate receptor (NMDA) receptors [66]. It was approved by FDA in August 1993 for the treatment of seizures associated with Lennox–Gastaut syndrome in children, but was withdrawn within a year in August 1994 due to its association with aplastic anemia [67]. Felbamate was provided a redemption in September 1994 for limited use in patients with refractory epilepsy [68], and with additional warning due to its association with rare incidence of acute liver failure, including cases with fatalities [67,69–71].